Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories


Daily deal net: May 7, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Dyno Therapeutics evolves to raise $100m
Advancing Harvard Medical School research, Dyno Therapeutics has raised $100m to advance its gene therapies based on AAV.
TwinStrand takes in $50m
UW spinout TwinStrand has completed a $50m series B round led by Section 32, while Alexandria Venture Investments invested a third time.
Mainspring Energy bounces to $95m series D
American Electric Power, Chevron and Equinor all participated in a round that increased the Stanford company’s total funding to $228m.
Affinia achieves $110m series B close
GV, Mass General Brigham Ventures and Lonza helped Affinia Therapeutics raise $110m to commercialise work originating at Harvard.
Solid Power recharges with $130m
CU Boulder’s solid-state battery provider pulled in funding through a series B round co-led by potential customers BMW and Ford.
Daily deal net: May 5, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Werewolf Therapeutics hunts $120m in IPO
The UPMC-backed cancer biotherapeutics developer priced its shares in the middle of their range in its initial public offering.

News Continued

Mogrify magnifies series A
Mogrify has collected $17m in a second series A tranche led by Parkwalk Advisors to bring the round’s total to $33m.
Zoe dishes up $20m series B
Ahren Innovation Capital has helped bring Zoe’s overall financing to $53m by leading a series B round for the personalised nutrition service. brings in $65m
Harvard University’s endowment has participated in a funding round for the robo-advisory platform.
Kuur inks $185m acquisition
Athenex will pay $70m upfront and up to $115m in milestone payments to acquire Kuur Therapeutics, providing exits to Baylor College and IP Group.
Inivata inspires $390m acquisition
NeoGenomics has exercised its option to buy Inivata, a precision cancer diagnostics company that was formed to exploit Cambridge and CRUK research seven years ago.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
test reg